We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Valeant Pharmaceuticals to Acquire Pedinol
News

Valeant Pharmaceuticals to Acquire Pedinol

Valeant Pharmaceuticals to Acquire Pedinol
News

Valeant Pharmaceuticals to Acquire Pedinol

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Valeant Pharmaceuticals to Acquire Pedinol"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Revenue for 2011 was approximately $18 million and the transaction is expected to be immediately accretive.

"The Pedinol business will be a strong fit alongside Valeant's dermatology franchise," stated J. Michael Pearson, Valeant's chairman and chief executive officer. "The podiatry market has similar characteristics to the dermatology market that we find attractive from a risk and reward aspect, and expanding into this area is a natural extension of our topical formulation development capabilities. Pedinol has over 85 years of experience in podiatry and a highly regarded national field sales organization, which are both key as we prepare for broader expansion into this market. We expect Pedinol's established presence in the podiatry market to be a valuable asset for Valeant."

Advertisement